Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation.
Journal: Journal Of Pediatric Hematology/oncology
Published:
Abstract
The authors describe a young boy with juvenile myelomonocytic leukemia (JMML) who relapsed 45 days after HLA and killer immunoglobulin-like receptor (KIR) mismatched unrelated donor bone marrow transplant (MMUD-BMT) and subsequently developed life-threatening graft-versus-host disease (GvHD). Treatment with 6-mercaptopurine (6-MP) appeared to control severe GvHD and possibly prevented recurrence of leukemic relapse.
Authors
Daniel Stachel, Alfred Leipold, Michaela Kuhlen, Chara Gravou Apostolatou, Kaimo Hirv, Peter Bader, Charlotte Niemeyer, Jörn Beck, Wolfgang Holter
Relevant Conditions